Overview

An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The investigators will provide Levetiracetam treatment to epilepsy subjects in Japan who are judged to benefit from continued treatment with Levetiracetam by the investigators and who are willing to continuously receive this drug.
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Etiracetam
Levetiracetam
Piracetam